

A novel p53-inducible gene, *PAG608*, encodes a nuclear zinc finger protein whose overexpression promotes apoptosis

David Israeli, Ellen Tessler, Ygal Haupt¹,
Adi Elkeles, Sylvia Wilder, Robert Amson²,
Adam Telerman² and Moshe Oren³

Department of Molecular Cell Biology, The Weizmann Institute of Science, Rehovot 76100, ¹The Lautenberg Center for General Tumor Immunology, The Hebrew University Hadassah Medical School, Jerusalem 91120, Israel and ²Fondation Jean Dausset, Centre d'Etude du Polymorphisme Humain, 27 Rue Juliette Dodu, F-75010 Paris, France

³Corresponding author
e-mail: LIOREN@dapsas1.weizmann.ac.il.

The biological effects of the p53 tumor suppressor protein are elicited, at least in part, through sequence-specific transactivation of a battery of target genes. The differential display method was employed towards identifying additional p53 target genes, with emphasis on genes whose induction may contribute to p53-mediated apoptosis. We report here the cloning of a novel p53-inducible gene, designated *PAG608*. *PAG608* transcripts are induced by DNA damage in a p53-dependent manner. *PAG608* encodes a nuclear zinc finger protein, which appears to localize preferentially to nucleoli when expressed at moderate levels in transfected cells. Transient overexpression of *PAG608* in human tumor-derived cells leads to distinctive changes in nuclear morphology, and can promote apoptosis. Together with additional p53 target genes, *PAG608* may therefore play a role in mediating the biological activities of p53.

Keywords: apoptosis/p53 tumor suppressor/*PAG608*/zinc finger protein

Introduction

The p53 tumor suppressor gene is subject to frequent mutations in human cancer. A major outcome of such mutations is inactivation of the biochemical and biological functions of the wild-type (wt) p53 protein (for recent p53 reviews, see Bates and Vousden, 1996; Gottlieb and Oren, 1996; Ko and Prives, 1996; Oren and Prives, 1996). Among the biological effects elicited by wt p53, the best documented are cell cycle arrest and apoptosis.

The wt p53 protein can exert an array of biochemical activities. Of these, the most notable is its ability to act as a transcriptional regulator (Bates and Vousden, 1996; Gottlieb and Oren, 1996; Ko and Prives, 1996; Oren and Prives, 1996). p53 is a *bona fide* positive transcription factor, capable of binding in a sequence-specific manner to well defined DNA elements and inducing the transcription of genes residing in the vicinity of such p53 response elements. In addition, p53 can repress the transcription of many other genes; here, however, direct sequence-specific

interactions between p53 and these genes are generally not involved.

The cell cycle inhibitory activity of p53 is believed to rely primarily on its ability to act as a sequence-specific transcriptional activator. The gene whose contribution to p53-mediated growth arrest is best understood is the p21^{Waf1} gene, encoding an inhibitor of cyclin-dependent kinases (Brugarolas *et al.*, 1995; Deng *et al.*, 1995; Waldman *et al.*, 1996). Other genes, such as *GADD45*, may also play a role in this response (Smith *et al.*, 1994). Less is presently known about the biochemical basis of p53-mediated apoptosis. Depending on the particular experimental system, sequence-specific transactivation (SST) can either be obligatory (Sabbatini *et al.*, 1995; Yonish-Rouach *et al.*, 1995; Attardi *et al.*, 1996; White, 1996) or dispensable (Caelles *et al.*, 1994; Haupt *et al.*, 1995b; Bates and Vousden, 1996) for apoptosis. It is most likely, though, that the optimal apoptotic effect of p53 requires a combination of both SST and other, SST-independent biochemical activities (Chen *et al.*, 1996; Haupt *et al.*, 1996; Wang *et al.*, 1996).

Among the target genes whose sequence-specific transactivation by wt p53 may promote apoptosis, the most notable is *bax* (Miyashita *et al.*, 1994; Selvakumaran *et al.*, 1994; Miyashita and Reed, 1995). Indeed, p53 mutants which retain the ability to activate numerous promoters, including that of p21^{Waf1}, but carry a selective defect in activation of the *bax* promoter, are competent for growth arrest but completely deficient for apoptosis (Friedlander *et al.*, 1996; Ludwig *et al.*, 1996). Other p53 target genes whose activation might contribute to apoptosis are IGF-BP3 (Buckbinder *et al.*, 1995; Friedlander *et al.*, 1996; Ludwig *et al.*, 1996) and the mammalian homolog of the *Drosophila seven in absentia* gene (Amson *et al.*, 1996; Nemani *et al.*, 1996).

The list of presently identified p53 target genes is probably still far from exhaustive. To search for additional target genes we took advantage of the differential display method (Liang and Pardee, 1992; Zhao *et al.*, 1996) already used successfully before for a similar purpose (Okamoto and Beach, 1994; Amson *et al.*, 1996). In particular, the aim was to identify genes which might contribute to p53-mediated apoptosis. Therefore, the cell system chosen as a source of differentially expressed transcripts was one in which induction of wt p53 activity causes massive apoptosis. We report here the cloning of a novel p53 target gene, designated *PAG608*. *PAG608* encodes a nuclear zinc finger protein, whose overexpression promotes apoptosis in transfected human tumor-derived cells.

Results

PAG608 mRNA is induced by p53

In order to clone transcripts whose levels are modulated upon induction of biochemically active wt p53, we took

advantage of LTR6 cells. LTR6 cells are derived from the p53-deficient mouse myeloid leukemia line M1, stably transfected with the temperature-sensitive p53 mutant p53val135 (Yonish-Rouach *et al.*, 1991, 1993). At 37.5°C, the p53val135 protein is predominantly in a mutant conformation, and does not exhibit biochemical and biological activities characteristic of wt p53. However, upon down-shift to 32°C, it resumes a wild-type-like conformation, leading to induction of the corresponding biochemical and biological activities (Michalovitz *et al.*, 1990). In the case of LTR6 cells, this results in massive p53-dependent apoptosis (Yonish-Rouach *et al.*, 1991, 1993). RNA was extracted from LTR6 cells, either maintained at 37.5°C or incubated for 4 h at 32°C. The two RNA populations were subjected to screening by the differential display method (Liang and Pardee, 1992; Zhao *et al.*, 1996); matched RNA samples from similarly treated parental, p53-null M1 cells served as controls for non-specific temperature effects. A non-exhaustive screen resulted in isolation of short PCR-amplified DNA fragments corresponding to six differentially expressed transcripts; three up-regulated and three others repressed in the presence of excess wt p53 activity (LTR6 cells, 32°C). Of the former, one was found to represent a member of the GLN long terminal repeat (LTR) family of mouse endogenous retrovirus-like elements (data not shown), already identified earlier as a target for direct transcriptional activation by p53 (Zauberman *et al.*, 1993). Sequencing of the other two p53-induced, short PCR-amplified DNA fragments suggested that they represent novel genes. Of these two, clone *PAG608* (p53-activated gene 608) displayed stronger and more consistent induction by p53, when assessed by semi-quantitative RT-PCR using RNA from LTR6 cells and from several other cell systems in which wt p53 activity can be elevated experimentally (see below, and data not shown). *PAG608* was therefore chosen for further study.

In order to confirm the differential display and RT-PCR data, Northern blot analysis was performed for *PAG608* mRNA. In the experiment shown in Figure 1, the probe consisted of the most 5' 2.5 kb of *PAG608* cDNA, comprising the entire coding region (see later for details of full-length cDNA isolation). *PAG608* expression was very strongly induced at 32°C in LTR6 cells (lanes 4–6), but not in parental M1 cells (lanes 2 and 3). Hence, induction is due to the presence of excess wt p53 activity, rather than to a non-specific temperature effect. In LTR6 cells, two main transcripts were detected: a larger one of ~7.5 kb and a smaller one of ~2.4 kb (Figure 1). A similar p53-dependent induction was observed in Clone 6 (Cl6) cells—rat embryo fibroblasts stably transfected with p53val135. In that case, the 7.5 kb transcript was most prominent (Figure 1, lane 1), along with a less abundant transcript of ~6.5 kb. The 2.4 kb transcript was expressed in Cl6 cells at very low levels, detectable only upon longer exposure.

Semi-quantitative RT-PCR revealed that *PAG608* induction reached near-maximal levels already within 2 h after temperature down-shift (Figure 2A). This is as fast as observed for well-established p53 target genes in this cell system (Zauberman *et al.*, 1993; Okamoto and Beach, 1994; Selvakumar *et al.*, 1994). Expression levels remained high for at least 16 h after temperature down-




Fig. 1. Northern blot analysis of *PAG608* gene expression. RNA was extracted from Clone 6 (Cl6), M1 and LTR6 cells, either growing continuously at 37.5°C or maintained at 32°C for the indicated number of hours before harvesting. Five µg of poly(A)⁺ RNA of each sample were subjected to agarose gel electrophoresis, transferred onto a nylon membrane and probed with a *PAG608* cDNA probe. The radiolabeled probe consisted of the most 5' 2.5 kb of *PAG608* cDNA, including the entire open reading frame (see below). The same membrane was subsequently re-probed for *GAPDH*. The positions of size markers and of 18S and 28S rRNA are indicated.

shift (Figure 2A). To assess the approximate fold induction of *PAG608* RNA, semi-quantitative RT-PCR was performed on serial dilutions of cDNA from LTR6 cells maintained for 4 h at 32°C. As seen in Figure 2B, comparison with undiluted cDNA from 37.5°C cells indicated a 10- to 20-fold increase at 32°C relative to the non-permissive temperature.

The fast induction kinetics of *PAG608* mRNA suggested strongly that the corresponding gene is a direct target of wt p53, rather than being induced as a secondary consequence of p53 activation. To support this conclusion further, *PAG608* induction was examined in the presence of the protein synthesis inhibitor cycloheximide. As seen in Figure 2C, cycloheximide did not interfere significantly with the p53-dependent increase in *PAG608* mRNA. The cycloheximide treatment inhibited protein synthesis by >90%, as determined by measuring [³⁵S]methionine incorporation (data not shown). Hence, *de novo* protein synthesis is not required for induction of *PAG608* gene expression by p53. This provides additional evidence that *PAG608* expression is regulated directly by wt p53.

***PAG608* mRNA is induced by DNA damage in a p53-dependent manner**

In both LTR6 and Cl6 cells, the temperature shift results in a vast, presumably non-physiological surge of wt p53 activity. To confirm that *PAG608* expression can be induced




Fig. 2. Analysis of *PAG608* mRNA induction in LTR6 cells. (A) Kinetics of induction. RNA was extracted from M1 and LTR6 cells either growing continuously at 37.5°C or maintained at 32°C for the indicated number of hours before harvesting. Semi-quantitative RT-PCR was performed with *PAG608*-specific primers, as described in Materials and methods. Identical aliquots of each indicated cDNA were amplified in parallel reactions in the presence of mouse *GAPDH*-specific primers. The number of amplification cycles was 25 or 21 for *PAG608* and *GAPDH*, respectively. (B) Quantification of the extent of *PAG608* induction at 32°C. RNA was extracted from LTR6 cells, either growing continuously at 37.5°C or after a 4 h incubation at 32°C, and subjected to reverse transcription. The indicated serial dilutions of the cDNA corresponding to 32°C, as well as non-diluted 37.5°C cDNA, were subjected to semi-quantitative PCR with *PAG608*-specific primers. (C) *PAG608* is induced in the presence of cycloheximide. LTR6 cells were subjected to treatment with 15 µg/ml cycloheximide (chx), or left without the drug. One hour later, cells were shifted to 32°C, or left at 37.5°C. After an additional 3 h, RNA was extracted. Equal amounts of each RNA sample were taken for cDNA synthesis. The indicated serial dilutions of the cDNA corresponding to 32°C, as well as non-diluted 37.5°C cDNA, were subjected to semi-quantitative PCR with *PAG608*-specific primers.

by activation of endogenous wt p53 under more physiological conditions, semi-quantitative RT-PCR was performed with RNA extracted from the thymuses of wild-type mice and p53 knock-out (p53^{-/-}) mice, either




Fig. 3. Induction of *PAG608* mRNA by DNA damage. (A) p53-deficient (p53^{-/-}) mice (Lowe *et al.*, 1993), as well as wild-type (WT) littermates, were obtained through a cross between a male and female p53^{+/-} mouse. One 40-day-old mouse of each type was exposed to 5 Gy of whole-body γ -irradiation (+ IR), and another pair was left unirradiated (- IR). Four hours later, total RNA was extracted from the thymus of each mouse, and 8 µg of RNA was taken for semi-quantitative RT-PCR with *PAG608*- and mouse *GAPDH*-specific primers. The number of amplification cycles was 27 or 23 for *PAG608* and *GAPDH*, respectively. (B) RNA was extracted from mouse myeloid 32D cells, either untreated (-) or exposed for 24 h to 1 µg/ml cisplatin (+). Semi-quantitative RT-PCR was performed as above. The number of amplification cycles was 23 or 19 for *PAG608* and *GAPDH*, respectively.




Fig. 4. Tissue distribution of *PAG608* mRNA. Total RNA was extracted from various tissues of an adult rat. Equal amounts (10 µg) of RNA from each tissue were subjected to 30 cycles of RT-PCR with *PAG608*-specific primers; the same cDNAs were subjected in parallel to 25 cycles of PCR with *GAPDH*-specific primers. B, brain; G, gut; H, heart; K, kidney; LI, liver; LU, lung; M, skeletal muscle; S, spleen; T, thymus.

untreated or 4 h after exposure to whole-body ionizing radiation. As seen in Figure 3A, a several fold increase in *PAG608* mRNA was observed upon irradiation of normal mice, but not of p53^{-/-} mice. Hence induction of DNA damage in the thymus, known to trigger vigorous p53-dependent apoptosis (Clarke *et al.*, 1993; Lowe *et al.*, 1993), also stimulates *PAG608* expression in a p53-dependent manner.

Induction of *PAG608* was also assayed in mouse myeloid 32D cells. 32D cells contain wt p53, which can be activated by DNA damage (Hiebert *et al.*, 1995). Treatment of these cells with cisplatin increases the expression of p21^{Waf1}, a prototype p53 target gene (G.Blandino and M.Oren, unpublished). In parallel, *PAG608* expression is also induced (Figure 3B). Thus, *PAG608* indeed behaves as expected of a proper p53 target gene.

To determine the *in vivo* expression pattern of *PAG608* transcripts, RNA was extracted from several rat tissues and subjected to RT-PCR. Expression could be detected in all tissues examined: the highest levels were encountered in brain, gut, lung and testis (Figure 4).

```

GCTTCCTGCAGCTGTTCCCTTGTGGCTCCGCTCCCACTGACTTTTGGACAATCAAT
CTCCAGCAACGGAGCGCGCATCGCGCGGGTGGAGCTCAGAAAAGTGGTGGAGCGGGG
CGGGCGCGGAGTGGCGGTGCGGCTGCGGCTGCCGGTTCGGTTTGAAGACTCCGTCCA
TCCCCTGTCAACCCACTGGATTATGCTCGTGGCTTCTCGCTGCTG
230 250 270
ATGATTCTTTTGCAGCAGGTCTGGCTTCCCTTACCTAACCCGCTTCAACCTCTCCCTCT
M I L L Q Q V W L P L P N R P S T S P P
290 310 330
ATGTGTCAGTGGCTGCCAGGTCCACTGGGACCTTGCAGCTCCCGCCACAGAAGGCTTTTGGG
M S V A A R S T G T L Q L P P Q K A F G
350 370 390
CAGGAAGCATCTTCCCTTGGCAGGGGAAGAGGATTTAGCTAAGAGAGGGGAGCCAGAT
Q E A S L P L A G E E D L A K R G E P D
410 430 450
TCTGCCCTGGAGGAGCTGTGTAAGCCCTCTCTGCAAACTGTGCAATGTCACTTGAAC
S A L E E L C K P L F C K L C N V T L L N
470 490 510
TCCGCTCAGCAAGCCAGGCCACTATCAGGGTAAAAACCATGGCAAGAACTCCGAAT
S A O Q A O A H Y O G K N H G K K L R N
530 550 570
TATTATGCAGCTAACAGCTGCCCTCCAGCCAGGATGAGCAGCGTGGCGGAGCCTGTA
Y Y A A N S C P P P A R M S S V A E P V
590 610 630
GCCACACCCTCGTCCCTGCTCCCTCCAGGTGGGCTCTGCAAGCCAGGGGCGAGGTTG
A T P L V P V P P Q V G S C K P G G R V
650 670 690
ATCTGGCCACAGAGAATGACTACTGTAAGCTGTGGATGCCTCCTCAGTCCCGCGG
I L A T E N D Y C K L C D A S P S S P A
710 730 750
GTGGCACAGGCGACTACCAGGGGAAGAACCAGCCCAAGAGACTTCGCTGGCCGAAGCT
V A O A H Y O G K N H A K R L R L A E A
770 790 810
CAGAGCCACTCATCTCGGACTCTGCAGAGCGGGGCAACCGCGGACCCGAAAGAAAGGG
Q S H S F S D S A E A G Q R R T R K E G
830 850 870
AGTGAATTTAAGATGGTACCACAGGAGGAATATGATACAGTCCAGAGCAATTCAGGT
S E F K M V T T R R N M Y T V Q S N S G
890 910 930
CCTTACTTCAACGCCCTTCTCGGCGAGGATCCCGGAGATCTCGCCATGTGCGTTACT
P Y F N A R S R Q R I P R D L A M C V T
950 970 990
CCAAGTGGCCAGTTTACTGCTCGATGTGTAACGTCGGAGCTGGCGAAGAGGTTGGAGTTC
P S G Q F Y C S M C N V G A G E V E F
1010 1030 1050
CGGCAGCATCTAGAGAGCAAGCAGCAAAAAGTAAGTGTCCGAGCAGCGGTACAGGAGC
R O H L E S K O H K S K V S E Q R Y R S
1070 1090 1400
GAGATGGAGAACCCTGGCTACGTTCACTGA .....GTACTCT
E M E N L G Y V Q *
CATGTATGTACTGATTTCTGATAAAGGCTGTATGATACTGTAACGGACTTTCTGTGTTCAG
7500
TTCATAAAACAGTTTCTGAGTCTCGTCTCCAAAAA

```

Fig. 5. Nucleotide and predicted protein sequence of *PAG608* cDNA. Shown are the first 1090 nucleotides of rat *PAG608* cDNA, comprising a short 5' UTR and an ORF encoding 289 amino acid residues, as well as the last 100 nucleotides of the cDNA. The three zinc finger motifs of the C2H2 type are underlined, with the critical cysteine and histidine residues indicated in bold letters. Also underlined are an in-frame upstream stop codon and the most 3' polyadenylation signal. Two additional polyadenylation signals, located at around nucleotide positions 2290 and 6400, are not shown.

PAG608 encodes a putative zinc finger protein

As a first step towards determining the full sequence of *PAG608* mRNA, the short differential display cDNA fragment, corresponding to the extreme 3' end of the mRNA, was employed for screening an LTR6 (32°C) cDNA library. This resulted in isolation of the most 3' 4.5 kb (out of 7.5 kb) of mouse *PAG608* mRNA. No conspicuous open reading frame (ORF) could be identified (data not shown). Longer *PAG608* clones, this time of rat origin, were therefore obtained by screening a cDNA library from Cl6 cells maintained at 32°C (Zauberman *et al.*, 1995). Analysis of several partially overlapping clones allowed us to derive a sequence spanning a total of 7.5 kb. This extends from the 3' end of the mRNA to a position very close to the transcriptional start site, as determined by Marathon RACE (data not shown). Overall, the sequence reveals a rather short 5'-untranslated region (5' UTR), followed by a relatively short ORF and a very long 3' UTR (Figure 5; only part of the 3' UTR is shown).




Fig. 6. Detection of endogenous and transfection-derived *PAG608* protein. LTR6 (lanes 3 and 4), Cl6 (lanes 5 and 6) and DP16val135 (lanes 7 and 8) cells were maintained at either 32 or 37.5°C, as indicated above each lane. Total cell extracts were subjected to Western blot analysis, using a polyclonal rabbit serum raised against a GST fusion protein containing the last 59 residues of the rat *PAG608* ORF. Lanes 1 and 9 contain extracts from p53-null human H1299 cells, transiently transfected with an expression plasmid (pHA-PAG608) encoding the full-length *PAG608* ORF fused at its N-terminus to a HA tag. Lane 2 contains an extract of mock-transfected H1299 cells.

The presence of an in-frame translation termination codon within the 5' UTR (see Figure 5) further supports the correct assignment of the first methionine of the ORF. This ORF predicts a protein of 289 amino acid residues, containing three conserved zinc finger motifs of the C2H2 type (Figure 5, underlined). No other distinctive motifs could be discerned.

The 7.5 kb RNA sequence most probably corresponds to the large rat *PAG608* transcript (Figure 1). Analysis of several partial cDNA clones, as well as PCR amplification of DNA from the cDNA library with several pairs of primers, did not provide evidence for alternative splicing (data not shown). The shorter transcripts shown in Figure 1 may thus represent products of alternative polyadenylation. In fact, analysis of the complete 7.5 kb cDNA sequence reveals potential polyadenylation signals at ~2.3 and 6.4 kb downstream from the transcriptional start site, respectively (data not shown). All corresponding transcripts are therefore expected to vary only at their 3' ends, and encode the same 289 amino acid protein.

Expression of the *PAG608* protein is induced in a p53-dependent manner

A polyclonal rabbit serum was raised against a GST fusion protein containing the last 59 residues of rat *PAG608*. Using this antiserum, strong induction of a polypeptide with an apparent M_r of 32 kDa, consistent with the expected size of *PAG608*, was observed at 32°C in LTR6, Cl6 and DP16val135 cells (Figure 6). The latter cells, derived by stable transfection of the mouse erythroleukemia DP16 cell line with p53val135, also undergo apoptosis when wt p53 activity is induced at 32°C (Johnson *et al.*, 1993). The antiserum also detected a corresponding polypeptide in human p53-null H1299 cells transfected with a plasmid in which the full *PAG608* ORF was fused at its N-terminus to a *Haemophilus influenzae* hemagglutinin (HA) tag (Figure 6, lanes 1 and 9), but not in mock-transfected H1299 cells (lane 2). As expected from the presence of the HA tag, the mobility of the fusion polypeptide was slightly slower than that of the endogenous *PAG608* protein.

These observations confirm that, like *PAG608* mRNA,

the PAG608 protein also accumulates in the presence of activated wt p53.

PAG608 is a nuclear protein

To determine the subcellular localization of the PAG608 protein, human Saos-2 osteosarcoma cells were transiently transfected with a *PAG608* expression plasmid. Forty eight hours later, cells were fixed and stained with the PAG608 antiserum; nuclear DNA was visualized in the same cells by simultaneous 4',6'-diamidino-2-phenylindole (DAPI) staining. In the majority of successfully transfected cells, the protein localized exclusively to the nucleus (Figure 7A and B). In a small percentage of cells, staining of variable intensity could also be observed in the cytoplasm (data not shown). The precise pattern of staining within the nucleus varied with the extent of PAG608 overexpression. In cells with relatively limited expression, the protein was localized primarily to a number of small regions within the nucleus, most likely representing nucleoli. This is exemplified by the cell at the bottom of Figure 7C; the corresponding DAPI staining is seen in Figure 7D, and a combined DAPI + phase image in Figure 7E. Cells with higher amounts of PAG608 protein displayed a more widespread nuclear staining. Examination of such cells at higher magnification revealed that in some of them the PAG608 protein was not uniformly distributed throughout the nucleus, but rather exhibited a heavily punctate pattern (Figure 7F). Remarkably, multiple speckles of condensed chromatin were evident within the corresponding nuclei (Figure 7G, and some additional examples in B and I); often, these speckles were most intense at positions from which PAG608 protein was excluded (compare Figure 7F with G and H with I).

It is noteworthy that a similar pattern, i.e. nucleolar staining at lower expression levels and wider nuclear staining at higher levels, has been reported for another zinc finger protein, LYAR (Su *et al.*, 1993).

Overexpression of PAG608 induces apoptosis

A transient transfection assay (Haupt *et al.*, 1995a) was employed in order to gain insight into the cellular consequences of PAG608 overexpression. To that end, Saos-2 and human lung adenocarcinoma H1299 cells were transiently transfected with a *PAG608* expression plasmid. Cultures were harvested 48 (Saos-2) or 66 h (H1299) later, fixed and stained for PAG608. Subsequently, the DNA of the same cells was stained with propidium iodide (PI). Appropriate gating in the FACS was then used to separate the successfully transfected cells, expressing high levels of PAG608, from the bulk of non-transfected cells (Figure 8A; the bar represents the boundary between the two sub-populations). The gated only, PAG608-overexpressing sub-population is shown in Figure 8B. Analysis of DNA content revealed that this gated sub-population exhibited a significantly higher fraction of cells with sub-G1 DNA content, indicative of apoptosis (Darzynkiewicz, 1995). This was observed for both H1299 cells (compare Figure 8D with C) and Saos-2 cells (compare Figure 8F with E). A two-parameter analysis (Figure 8K and L) revealed that many of the sub-G1 cells were of a size similar to or only slightly smaller than the rest of the cells. Hence, these sub-G1 cells most probably represent true apoptotic cells rather than random small cellular




Fig. 7. Immunological detection of PAG608 protein in transiently transfected cells. Human p53-null Saos-2 cells were transiently transfected with pHA-PAG608. Then 48 h later, cells were fixed and double stained with the anti-PAG608 rabbit polyclonal serum and with DAPI. (A) and (B) The PAG608 and DAPI staining, respectively, of the same microscopic field; a second field is shown in (F) and (G). (C, D and E) The PAG608, DAPI and phase + DAPI pictures, respectively, of a third field; a fourth field is presented in (H), (I) and (J). DAPI-stained nuclei correspond to the entire cell population, only a fraction of which is transfected successfully with the *PAG608* expression plasmid. Arrows in (H) (I) and (J) indicate PAG608-positive 'ghosts', presumably in advanced stages of apoptosis, with minimal residual DNA; the arrowhead indicates a cell with non-uniform nuclear PAG608 distribution, speckles of condensed chromatin and extensive cytoplasmic shrinkage.

debris. In addition, in H1299 but not Saos-2 cells, there was also a reproducible increase in the fraction of cells in G2/M, the nature of which is presently unclear. The combined data from three independent transfection experiments is presented in Figure 9; the differential effect of PAG608 overexpression is less impressive in Saos-2 cells, owing to a variably high background of spontaneous apoptosis in cultures of this cell line.

For controls, Saos-2 cultures were transfected in parallel with expression plasmids for different forms of p53. These

cultures were then analyzed as above, except that a p53-specific monoclonal antibody was used for gating (Haupt *et al.*, 1995a). Overexpression of wt p53 elicited substantial apoptosis in Saos-2 cells (compare Figure 8H with G), in line with earlier reports (Yonish-Rouach *et al.*, 1995; Haupt and Oren, 1996; Rowan *et al.*, 1996). By contrast, no such effect was exerted by mutant p53dl(13–52) (Figure 8I and J), which contains a deletion within the transactivation domain and is deficient in the induction of apoptosis (Haupt *et al.*, 1995b).

Many cells within the PAG608-positive sub-population displayed a variety of nuclear aberrations characteristic of apoptosis (Figure 7). These included deformed or fragmented nuclei, regions of intense DAPI staining, cytoplasmic shrinkage (arrowhead, Figure 7J) and ‘ghosts’, where hardly any chromosomal DNA was left (arrows, Figure 7H and J). Moreover, cells displaying heavy speckles of condensed chromatin also stained positive by TUNEL (Figure 10). Thus, high levels of PAG608 protein can promote apoptosis in at least two distinct cell lines.

Discussion

In the present study, we report the cloning and characterization of a novel gene, designated *PAG608*, whose expression is strongly activated by wt p53. When overexpressed in transfected cells, the relatively small zinc finger protein encoded by *PAG608* exhibits a predominantly nuclear localization, although it does not contain a canonical nuclear localization signal. Moreover, the staining pattern of the transfected protein suggests that it is localized preferentially to nucleoli. So far, however, we have been unable to obtain unequivocal staining of the endogenous *PAG608* protein in non-transfected cells, suggesting that it is present in rather low amounts. The nucleolar localization of the *PAG608* protein is compatible with a possible role in regulation of rRNA synthesis. Interestingly, the pRb protein, product of another tumor suppressor gene, has been shown to accumulate in nucleoli and block the transcriptional activity of RNA polymerase I, and this has been suggested as an alternative anti-proliferative mechanism (Cavanaugh *et al.*, 1995). It is tempting to speculate that *PAG608*, too, may mediate particular inhibitory effects through interference with optimal production of new ribosomes.

The biological significance of p53-mediated *PAG608* induction remains unknown, as is also largely still the case for some of the better-known p53 target genes. Nevertheless, the conspicuous induction of *PAG608* in cells undergoing p53-dependent apoptosis, and particularly its ability to promote apoptosis in transiently transfected cells, raise the possibility that it plays some role in facilitating the apoptotic activities of p53. It should be borne in mind that, unlike what one observes upon extensive overexpression of *PAG608*, it seems rather unlikely that physiological induction of any single p53 target protein will suffice by itself to trigger apoptosis efficiently. Under physiological conditions, p53-mediated




Fig. 8. Induction of apoptosis in H1299 and Saos-2 cells by transient overexpression of *PAG608*. Cells plated at a density of 10^6 per 10 cm dish were transfected with expression plasmids encoding the following proteins under control of the CMV early enhancer/promoter: *PAG608* (A–F, K and L), wild-type mouse p53 (G and H) or the mouse p53 deletion mutant p53dl(13–52) (I and J). Forty eight (Saos-2) or 66 h (H1299) later, adherent and floating cells were combined, fixed with methanol, stained with antibodies specific for the corresponding transfection-derived protein and with propidium iodide (to visualize DNA content), and analyzed by flow cytometry. The polyclonal *PAG608* antiserum was used for (A–F), and (K) and (L), whereas the p53-specific monoclonal antibody PAb421 was employed for (G–J). To differentiate the successfully transfected cells from the bulk non-transfected population in each culture, specific protein staining was plotted as a function of cell size (forward scatter), illustrated in A for *PAG608*-transfected Saos-2 cells. *PAG608* fluorescence is plotted on a logarithmic scale. Small cellular debris was eliminated by leaving out all particles whose size (forward scatter) was substantially below that of the cells in the bulk population. A gate (denoted by bar in A) was then set, and cells with high *PAG608* staining (above the bar) were monitored separately. The size and fluorescence distribution of the high-*PAG608* cells are shown in (B). The DNA content distributions of the total (A) and gated (B) populations are depicted in (E) and (F), respectively. A similar gating and analysis protocol was also employed for *PAG608* in H1299 cells (C and D), as well as for p53 (G–J). The horizontal bar in (C–J) denotes the position of cells with sub-G1 DNA content, indicative of apoptosis; the percentage of sub-G1 cells within the total population is indicated above the bar. (K and L) A two-parameter presentation of the same cells as shown in (C) and (D), where DNA content is plotted as a function of cell size for the total (K) and the *PAG608*-positive (L) populations.




Fig. 9. Induction of apoptosis by *PAG608* overexpression. Graphical representation of the flow cytometric analysis of *PAG608*-transfected cultures. Experimental details are as described in Figure 8. Each column represents at least three independent transfection experiments. Standard deviation is indicated by vertical bars.

apoptosis appears to be elicited through the combined effect of several distinct pathways; only some of these pathways rely on the ability of p53 to act as a sequence-specific transcriptional activator of target genes (Haffner and Oren, 1995; Bates and Vousden, 1996; Gottlieb and Oren, 1996). Moreover, despite the centrality of *bax* in that latter group of target genes (Miyashita *et al.*, 1994; Selvakumaran *et al.*, 1994; Miyashita and Reed, 1995; White, 1996), it is most probable that *bax* is only one of several genes whose activation by p53 contributes to apoptosis. Our data suggest that *PAG608* may be another member of this group, perhaps acting through a mechanism totally unrelated to that of *bax*. Recent studies suggest that the transcriptional regulation of apoptosis-mediating genes by p53 may be uncoupled, under certain circumstances, from that of growth arrest-mediating genes (Bates and Vousden, 1996; Friedlander *et al.*, 1996; Ludwig *et al.*, 1996). It will therefore be of interest to find out whether *PAG608* gene expression is also subject to similar differential regulation.

Further insight into the biological role of *PAG608* is likely to be gained once its biochemical functions are better understood. For the time being, the main clue is the presence of the three zinc fingers. This feature might suggest binding to nucleic acids, although an involvement in specific protein-protein interactions cannot be ruled out either. It is of note that several p53 target genes encode zinc finger proteins; these include *mdm2* (Barak *et al.*, 1993; Wu *et al.*, 1993), *HIC-1*, a putative tumor suppressor gene (Wales *et al.*, 1995), the mammalian homolog of the *Drosophila seven in absentia* gene (Amson *et al.*, 1996; Nemani *et al.*, 1996), and now *PAG608*. In addition, the p53 protein forms physical associations with several zinc finger proteins, including WT1 (Maheswaran *et al.*, 1995) and also Mdm2 (Momand *et al.*, 1992; Oliner *et al.*, 1992; Barak *et al.*, 1993). Thus, nuclear processes involving the activity of zinc finger proteins appear to represent a favorite target for modulation by p53. Future work on *PAG608* will hopefully allow better elucidation of the nature of these processes.




Fig. 10. *PAG608*-induced nuclear alterations correlate with positive TUNEL staining. Saos-2 cells were transiently transfected with *PAG608* as described for Figure 7, fixed in paraformaldehyde and subjected simultaneously to TUNEL analysis (A) and DAPI staining (B).

Materials and methods

Cell lines

M1 and LTR6 cells were maintained routinely at 37.5°C in RPMI supplemented with 10% fetal calf serum (FCS). 32D cells were maintained in RPMI supplemented with 10% FCS and 0.1% medium conditioned by X63/0 cells (Karasuyama and Melchers, 1988) serving as a source of interleukin-3. Cl6, Saos-2 and DP16val135 cells were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% FCS.

Differential display cDNA cloning

Differential display cDNA cloning of p53-inducible transcripts, using RNA from M1 and LTR6 cells maintained either at 32 or at 37.5°C, was performed essentially as described before (Amson *et al.*, 1996). In the present study, three 3' primers (out of a total of four) were used in combination with four 5' primers (out of a total of 12), and only part of the differentially displayed bands were taken for further analysis. Thus, the screening was non-exhaustive.

Semi-quantitative RT-PCR

Total RNA was extracted by the RNeasyTM (TEL-TEST, Inc.) procedure. First-strand cDNA was synthesized with M-MLV reverse transcriptase (Promega) in the presence of 10 µg of RNA, 0.25 µg of oligo(dT) primer, 0.5 mM each of dATP, dCTP, dGTP and dTTP, 25 mM Tris-HCl pH 8.3, 37.5 mM KCl, 1.5 mM MgCl₂, 5 mM dithiothreitol (DTT) and 200 U of M-MLV reverse transcriptase, in a final volume of 20 µl. For each PCR reaction, we used 1 µl of cDNA, 0.1 mM each of dATP, dCTP, dGTP and dTTP, 2 U of *Taq* polymerase (Advanced Biotechnologies), 1× of the corresponding reaction buffer (provided with the enzyme) and a pair of primers specific for either *PAG608* or *GAPDH* (0.75 µM each).

The following primer combinations were used: *PAG608*, 5'-CTTTTGGT-TTTTTATTTCCTTCAGCC3' and 5'-ACAGCCAAGATGAGCCAACG-TAA3'; *GAPDH*, 5'-CAGCAATGCATCCTGCACC3' and 5'-TGGACT-GTGGTCATGAGCCC3'. A limiting cycle amplification protocol was used in order to maintain the PCR reaction within its linear range. To determine the optimal number of amplification cycles for each pair of primers, aliquots of the corresponding PCR reactions were withdrawn for agarose gel analysis after a minimal number of cycles. The reaction was then resumed for two additional cycles, and aliquots were withdrawn

again. This procedure was repeated several more times, with an increasing number of cycles. The presented data were obtained with the minimal number of cycles sufficient for detecting clearly visible PCR bands.

Northern blot analysis

Northern blot was performed as described before (Barak *et al.*, 1993), using a *PAG608* cDNA probe or a *GAPDH* control probe.

DNA sequencing

DNA sequencing was performed by the Weizmann Institute DNA sequencing unit, with the aid of an ABI 373 automatic sequencer. Sequence analysis was carried out with the DNA sequence assembly software AutoAssembler™ (ABI).

Production of PAG608-specific antiserum

The last 59 residues of the *PAG608* ORF were fused in-frame with GST, in the pGEX3 plasmid (Pharmacia). The fusion protein was overexpressed in bacteria and purified as described (Barak *et al.*, 1993), and then used for immunization of New Zealand White rabbits.

Protein analysis

Total cell extracts were analyzed by Western blotting as described (Barak *et al.*, 1993), using the rabbit PAG608 antiserum followed by protein A-conjugated horseradish peroxidase. The blots were developed with the ECL chemiluminescence system (Amersham).

Flow cytometry

H1299 or Saos-2 cells were plated 24 h before transfection at a density of 1.2×10^6 cells per 10 cm dish. Cells were transfected by the calcium phosphate co-precipitation method, as described before (Haupt *et al.*, 1995b). The precipitate was left on the cells for 4–6 h (Saos-2) or overnight (H1299). Amounts of transfected plasmid DNA per 10 cm dish were 3 and 10 μ g for p53 and *PAG608*, respectively. At 48 (Saos-2) or 66 h (H1299) post-transfection, adherent and floating cells were collected together and fixed in methanol. Fixed cells were resuspended and incubated in phosphate-buffered saline (PBS) at 4°C for at least 10 min. Subsequently, the cells were reacted with the primary antibody (PAG608-specific antiserum or the p53-specific monoclonal antibody PAb421, as appropriate). PI (Sigma) was added to the cell suspension to a final concentration of 50 μ g/ml, and cells were analyzed in a cell sorter (FACSort, Becton Dickinson). Cells were first monitored for overexpression of the transfected gene product, by determining their fluorescein isothiocyanate (FITC) fluorescence intensity. A threshold ('gate') defining the high FITC sub-population was set empirically (see Results). Equal numbers of cells from the total population and from the gated, protein-overexpressing sub-population were recorded separately for PI staining.

Immunofluorescence microscopy

Saos-2 cells were plated on glass coverslips within 6 cm tissue culture dishes. Transfections were as described above. Cells were washed in ice-cold PBS, fixed in cold methanol (–20°C) for at least 20 min and rehydrated in ice-cold PBS for at least 30 min. Following incubation with rabbit anti-PAG608 serum for 60 min at room temperature, coverslips were washed three times with PBS and incubated with rhodamine-conjugated donkey anti-rabbit IgG (Jackson Immunoresearch Laboratories) for 30 min at room temperature. The last incubation contained DAPI (Sigma) at a concentration of 0.5 μ g/ml. Coverslips were washed three times in PBS, mounted over glass slides and viewed under a fluorescence microscope (Zeiss Axioscop).

TUNEL analysis

Cells were plated on coverslips, transfected and harvested as described above, fixed in 3% paraformaldehyde for 30 min at room temperature and washed in PBS. The fixed coverslips were rinsed and incubated in the reaction buffer provided by the supplier (Boehringer), supplemented with 1.5 mM CoCl_2 , 40 μ M biotin-16-dUTP (Boehringer) and 10 U of terminal deoxynucleotidyl transferase (Boehringer) for 1 h at 37°C. Coverslips were then washed for 15 min in $20 \times$ SSC, rinsed twice in PBS, and incubated for 30 min at 37°C with PBS containing ExtraAvidin-TRITC, and DAPI at 0.5 μ g/ml. Following two washes in PBS, the coverslips were mounted over glass slides and viewed under the fluorescence microscope.

Accession number

The DDBJ/EMBL/GenBank accession number for the *PAG608* sequence is Y13148.

Acknowledgements

We thank A.Amsterdam for help and advice on fluorescent microscopy, S.Benchimol for DP16val135 cells, M.Tal for the LTR6 library, A.Zauberman for the Clone 6 cDNA library and S.Friedmann for advice and suggestions. This work was supported in part by PHS grant RO1 CA 40099 from the National Cancer Institute, by a grant from the Israel–USA Binational Science Foundation and by the Leo and Julia Forchheimer Center for Molecular Genetics.

References

- Amson,R.B. *et al.* (1996) Isolation of 10 differentially expressed cDNAs in p53-induced apoptosis: activation of the vertebrate homologue of the *Drosophila seven in absentia* gene. *Proc. Natl Acad. Sci. USA*, **93**, 3953–3957.
- Attardi,L.D., Lowe,S.W., Brugarolas,J. and Jacks,T. (1996) Transcriptional activation by p53, but not induction of the p21 gene, is essential for oncogene-mediated apoptosis. *EMBO J.*, **15**, 3693–3701.
- Barak,Y., Juven,T., Haffner,R. and Oren,M. (1993) *mdm2* expression is induced by wild type-p53 activity. *EMBO J.*, **12**, 461–468.
- Bates,S. and Vousden,K.H. (1996) p53 in signaling checkpoint arrest or apoptosis. *Curr. Opin. Genet. Dev.*, **6**, 12–18.
- Brugarolas,J., Chandrasekaran,C., Gordon,J.I., Beach,D., Jacks,T. and Hannon,G.J. (1995) Radiation-induced cell cycle arrest compromised by p21 deficiency. *Nature*, **377**, 552–557.
- Buckbinder,L., Talbot,R., Velasco-miguel,S., Takenaka,I., Faha,B., Seizinger,B.R. and Kley,N. (1995) Induction of the growth inhibitor IGF-binding protein 3 by p53. *Nature*, **377**, 646–649.
- Caelles,C., Helmsberg,A. and Karin,M. (1994) p53-dependent apoptosis in the absence of transcriptional activation of p53-target genes. *Nature*, **370**, 220–223.
- Cavanaugh,A.H., Hempel,W.M., Taylor,L.J., Rogalsky,V., Todorov,G. and Rothblum,L.I. (1995) Activity of RNA polymerase I transcription factor UBF blocked by RB gene product. *Nature*, **374**, 177–180.
- Chen,X., Ko,L.J., Jayaraman,L. and Prives,C. (1996) p53 levels, functional domains, and DNA damage extent determine the extent of the apoptotic response of tumor cells. *Genes Dev.*, **10**, 2438–2451.
- Clarke,A.R., Purdie,C.A., Harrison,D.J., Morris,R.G., Bird,C.C., Hooper,M.L. and Wyllie,A.H. (1993) Thymocyte apoptosis induced by p53-dependent and independent pathways. *Nature*, **362**, 849–852.
- Darzynkiewicz,Z. (1995) Apoptosis in antitumor strategies: modulation of cell cycle or differentiation. *J. Cell Biochem.*, **58**, 151–159.
- Deng,C.X., Zhang,P.M., Harper,J.W., Elledge,S.J. and Leder,P. (1995) Mice lacking p21(C/P1/WAF1) undergo normal development, but are defective in G1 checkpoint control. *Cell*, **82**, 675–684.
- Friedlander,P., Haupt,Y., Prives,C. and Oren,M. (1996) A mutant p53 that discriminates between p53-responsive genes cannot induce apoptosis. *Mol. Cell Biol.*, **16**, 4961–4971.
- Gottlieb,T.M. and Oren,M. (1996) p53 in growth control and neoplasia. *Biochim. Biophys. Acta*, **1287**, 77–102.
- Haffner,R. and Oren,M. (1995) Biochemical properties and biological effects of p53. *Curr. Opin. Genet. Dev.*, **5**, 84–90.
- Haupt,Y. and Oren,M. (1996) p53-mediated apoptosis: mechanisms and regulation. *Behring Institute Mitteilungen*, **97**, 32–59.
- Haupt,Y., Rowan,S. and Oren,M. (1995a) p53-mediated apoptosis in HeLa cells can be overcome by excess pRB. *Oncogene*, **10**, 1563–1571.
- Haupt,Y., Rowan,S., Shaulian,E., Vousden,K.H. and Oren,M. (1995b) Induction of apoptosis in HeLa cells by transactivation-deficient p53. *Genes Dev.*, **9**, 2170–2183.
- Haupt,Y., Barak,Y. and Oren,M. (1996) Cell type-specific inhibition of p53-mediated apoptosis by *mdm2*. *EMBO J.*, **15**, 1596–1606.
- Hiebert,S.W., Packham,G., Strom,D.K., Haffner,R., Oren,M., Zambetti,G. and Cleveland,J.L. (1995) E2F-1:DP-1 induces p53 and overrides survival factors to trigger apoptosis. *Mol. Cell Biol.*, **15**, 6864–6874.
- Johnson,P., Chung,S. and Benchimol,S. (1993) Growth suppression of Friend virus-transformed erythroleukemia cells by p53 protein is accompanied by hemoglobin production and is sensitive to erythropoietin. *Mol. Cell Biol.*, **13**, 1456–1463.
- Karasuyama,H. and Melchers,F. (1988) Establishment of mouse cell lines which constitutively secrete large quantities of interleukin 2, 3, 4 or 5, using modified cDNA expression vectors. *Eur. J. Immunol.*, **18**, 97–84.
- Ko,L.J. and Prives,C. (1996) p53: puzzle and paradigm. *Genes Dev.*, **10**, 1054–1072.

- Liang,P. and Pardee,A.B. (1992) Differential display of eukaryotic messenger RNA by means of the polymerase chain reaction. *Nature*, **257**, 967–971.
- Lowe,S.W., Schmitt,E.M., Smith,S.W., Osborne,B.A. and Jacks,T. (1993) p53 is required for radiation-induced apoptosis in mouse thymocytes. *Nature*, **362**, 847–849.
- Ludwig,R.L., Bates,S. and Vousden,K.H. (1996) Differential activation of target cellular promoters by p53 mutants with impaired apoptotic function. *Mol. Cell. Biol.*, **16**, 4952–4960.
- Maheswaran,S., Englert,C., Bennett,P., Heinrich,G. and Haber,D.A. (1995) The WT1 gene product stabilizes p53 and inhibits p53-mediated apoptosis. *Genes Dev.*, **9**, 2143–2156.
- Michalovitz,D., Halevi,O. and Oren,M. (1990) Conditional inhibition of transformation and of cell proliferation by temperature-sensitive mutant of p53. *Cell*, **62**, 671–680.
- Miyashita,T. and Reed,J.C. (1995) Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. *Cell*, **80**, 293–299.
- Miyashita,T., Krajewski,S., Krajewska,M., Wang,H.G., Lin,H.K., Liebermann,D.A., Hoffman,B. and Reed,J.C. (1994) Tumor suppressor p53 is a regulator of *bcl-2* and *bax* gene expression *in vitro* and *in vivo*. *Oncogene*, **9**, 1799–1805.
- Momand,J., Zambetti,G.P., Olson,D.C., George,D. and Levine,A.J. (1992) The *mdm-2* oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. *Cell*, **69**, 1237–1245.
- Nemani,M. et al. (1996) Activation of the human homologue of the *Drosophila sina* gene in apoptosis and tumor suppression. *Proc. Natl Acad. Sci. USA*, **93**, 9039–9042.
- Okamoto,K. and Beach,D. (1994) Cyclin G is a transcriptional target of the p53 tumor suppressor protein. *EMBO J.*, **13**, 4816–4822.
- Oliner,J.D., Kinzler,K.W., Meltzer,P.S., George,D.L. and Vogelstein,B. (1992) Amplification of a gene encoding a p53-associated protein in human sarcomas. *Nature*, **358**, 80–83.
- Oren,M. and Prives,C. (1996) p53: upstream, downstream and off stream. *Biochim. Biophys. Acta*, **1288**, R13–R19.
- Rowan,S., Ludwig,R.L., Haupt,Y., Bates,S., Lu,X., Oren,M. and Vousden,K.H. (1996) Specific loss of apoptotic but not cell-cycle arrest function in a human tumor derived p53 mutant. *EMBO J.*, **15**, 827–838.
- Sabbatini,P., Lin,J.Y., Levine,A.J. and White,E. (1995) Essential role for p53-mediated transcription in E1A-induced apoptosis. *Genes Dev.*, **9**, 2184–2192.
- Selvakumaran,M., Lin,H.K., Miyashita,T., Wang,H.G., Krajewski,S., Reed,J.C., Hoffman,B. and Liebermann,D. (1994) Immediate early up-regulation of bax expression by p53 but not TGF beta 1: a paradigm for distinct apoptotic pathways. *Oncogene*, **9**, 1791–1798.
- Smith,M.L., Chen,I.T., Zhan,Q.M., Bae,I.S., Chen,C.Y., Gilmer,T.M., Kastan,M.B., O'Connor,P.M. and Fornace,A.J. (1994) Interaction of the p53-regulated protein *GADD45* with proliferating cell nuclear antigen. *Science*, **266**, 1376–1380.
- Su,L., Hershberger,R.J. and Weissman,I.L. (1993) LYAR, a novel nucleolar protein with zinc finger DNA-binding motifs, is involved in cell growth regulation. *Genes Dev.*, **7**, 735–748.
- Waldman,T., Lengauer,C., Kinzler,K.W. and Vogelstein,B. (1996) Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21. *Nature*, **381**, 713–716.
- Wales,M.M., Biel,M.A., Eldeiry,W., Nelkin,B.D., Issa,P., Cavenee,W.K., Kuerbitz,S.J. and Baylin,S.B. (1995) p53 activates expression of HIC-1, a new candidate tumour suppressor gene on 17p13.3. *Nature Med.*, **1**, 570–577.
- Wang,X.W. et al. (1996) The XPB and XPD DNA helicases are components of the p53-mediated apoptosis pathway. *Genes Dev.*, **10**, 1219–1232.
- White,E. (1996) Life, death, and the pursuit of apoptosis. *Genes Dev.*, **10**, 1–15.
- Wu,X.W., Bayle,J.H., Olson,D. and Levine,A.J. (1993) The p53 mdm-2 autoregulatory feedback loop. *Genes Dev.*, **7**, 1126–1132.
- Yonish-Rouach,E., Resnitzky,D., Lotem,J., Sachs,L., Kimchi,A. and Oren,M. (1991) Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. *Nature*, **352**, 345–347.
- Yonish-Rouach,E., Grunwald,D., Wilder,S., Kimchi,A., May,E., Lawrence,J.J., May,P. and Oren,M. (1993) p53-mediated cell death—relationship to cell cycle control. *Mol. Cell. Biol.*, **13**, 1415–1423.
- Yonish-Rouach,E., Deguin,V., Zaitchouk,T., Breugnot,C., Mishal,Z., Jenkins,J.R. and May,E. (1995) Transcriptional activation plays a role in the induction of apoptosis by transiently transfected wild-type p53. *Oncogene*, **11**, 2197–2205.
- Zauberman,A., Barak,Y., Ragimov,N., Levy,N. and Oren,M. (1993) Sequence-specific DNA binding by p53—identification of target sites and lack of binding to p53–MDM2 complexes. *EMBO J.*, **12**, 2799–2808.
- Zauberman,A., Lupo,A. and Oren,M. (1995) Identification of p53 target genes through immune selection of genomic DNA: the cyclin G gene contains two distinct p53 binding sites. *Oncogene*, **10**, 2361–2366.
- Zhao,S., Ooi,S.L., Yang,F.-C. and Pardee,A.B. (1996) Three methods for identification of true positive cloned cDNA fragments in differential display. *Biotechniques*, **20**, 402–406.

Received on February 17, 1997; revised on April 28, 1997